Growth hormone response to standard provocative stimuli and combined tests in very young children with Prader-Willi syndrome.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this clinical trial publication.

The researchers evaluated the pattern of GH secretion in very young PWS patients.

Who Took Part

The abstract describes 13 patients taking part.

PubMed indexes the participants as infants and young children, both men and women.

Twenty-seven genetically confirmed PWS children (10 females, aged 0.4-5 years, mean: 2.2 ± 1.4 years) were included.

All subjects underwent standard provocative tests (clonidine, CLO; and arginine, ARG) and one combined test [growth hormone-releasing hormone (GHRH) plus pyridostigmine (13 patients) or GHRH plus arginine (14 patients)].

How the Study Was Run

Insulin-like growth factor-1 (IGF-1) levels were also measured.

What Was Measured

The researchers evaluated the pattern of GH secretion in very young PWS patients.

PubMed files the paper under topics including Adrenergic alpha-2 Receptor Agonists, Arginine, Cholinesterase Inhibitors, Clonidine, Growth Hormone-Releasing Hormone, Human Growth Hormone and Prader-Willi Syndrome.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 13 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2014 (Hormone research in paediatrics), a journal based in Switzerland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.